Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology

Fitoterapia

Volumn 100, Issue , 2015, Pages 56-67

  Showman, Angelique F ^a,b   Baker, Jonathan D ^b   Linares, Christina ^a   Naeole, Chrystie K ^a   Borris, Robert ^c   Johnston, Edward ^e   Konanui, Jerry ^e   Turner, Helen ^a,b,d  

^a CHAMINADE UNIVERSITY OF HONOLULU   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII AT HILO   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e Association for Hawaiian 'Awa   (United States)

Author keywords

Kava; Kavalactones; Piper methysticum

Indexed keywords

CYTOCHROME P450; FLAVOKAWAIN B; KAVA; UNCLASSIFIED DRUG; LACTONE;

CHEMOPROPHYLAXIS; ENANTIOMER; EXTRACTION; GENETIC ASSOCIATION; HUMAN; LIVER TOXICITY; MEDICAL LITERATURE; NONHUMAN; PIPER METHYSTICUM; PLANT ROOT; REVIEW; ANIMAL; BEVERAGE; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; MALE; METABOLISM; MOUSE; RAT; TOXICITY; UNITED STATES;

PIPER METHYSTICUM;

ANIMALS; BEVERAGES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HAWAII; HUMANS; KAVA; LACTONES; MALE; MICE; MOLECULAR STRUCTURE; RATS;

EID: 84918772210     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2014.11.012     Document Type: Review

References (104)

1. E. Johnston, and H. Rogers Hawaiian awa: views of an ethnobotanical treasure 2006 Association for Hawaiian Awa Hilo, Hawaii
2. V. Lebot Kava: the Pacific drug L. Lindstrom, M. Merlin, 1992 Yale University Press New Haven
3. M. Pukui, E. Haertig, and C. Lee Nana I Ke Kumu (look to the source) 1983 Hui Hanai Honolulu, Hawaii
4. M. Titcomb Kava in Hawaii J Polynesian Soc. 57 2 1948 105 117
5. P. Petard Du kava ou ava J Pharm XII 1826 122
6. J.D. Baker Pills, potions, products: kava's transformations in new and nontraditional contexts Contemp Pac 24 2 2012 233 265
7. A.R. Clough, R. Baille, C.B. Burns, T. Guyula, R. Wunungmurra, and S.R. Wanybarrnga Validity and utility of community health workers' estimation of kava use Aust N Z J Public Health 26 1 2002 52 57
8. A. Denham, M. McIntyre, and J. Whitehouse Kava - the unfolding story: report on a work-in-progress J Altern Complement Med 8 3 2002 237 263
9. J.D. Baker Tradition and toxicity: evidential cultures in the kava safety debate Soc Stud Sci 41 3 2011 361 384
10. J. Gruenwald, and J. Skrabal Kava ban highly questionable: a brief summary of the main scientific findings presented in the "in depth investigation on EU member states market restrictions on kava products" Semin Integr Med 1 4 2003 199 210
11. S. Russmann, B.H. Lauterburg, and A. Helbling Kava hepatotoxicity Ann Intern Med 135 1 2001 68
12. Y. Yamazaki, H. Hashida, A. Arita, K. Hamaguchi, and F. Shimura High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats Food Chem Toxicol 46 12 2008 3732 3738
13. P.P. Fu, Q. Xia, L. Guo, H. Yu, and P.C. Chan Toxicity of kava kava Environ Carcinog Ecotoxicol Rev 26 1 2008 89 112
14. W.N. Richardson, and L. Henderson The safety of kava: a regulatory perspective Br J Clin Pharmacol 64 4 2007 418 420
15. CDC From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products - United States, Germany, and Switzerland, 1999-2002 JAMA 289 1 2003 36 37
16. M. Chiappedi, S. de Vincenzi, and M. Bejor Nutraceuticals in psychiatric practice Recent Pat CNS Drug Discov 7 2 2012 163 172
17. C. Feucht, and D.R. Patel Herbal medicines in pediatric neuropsychiatry Pediatr Clin North Am 58 1 2011 33 54
18. A. Fugh-Berman "Bust enhancing" herbal products Obstet Gynecol 101 6 2003 1345 1349
19. E. Heiligenstein, and G. Guenther Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian, and kava-kava J Am Coll Health 46 6 1998 271 276
20. S.E. Lakhan, and K.F. Vieira Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review Nutr J 9 2010 42
21. C.A. Morris, and J. Avorn Internet marketing of herbal products JAMA 290 11 2003 1505 1509
22. S.A. Saeed, R.M. Bloch, and D.J. Antonacci Herbal and dietary supplements for treatment of anxiety disorders Am Fam Physician 76 4 2007 549 556
23. S. Stacy Relaxation drinks and their use in adolescents J Child Adolesc Psychopharmacol 21 6 2011 605 610
24. A. Jowitt, and J. Binihi The commercialisation of kava in Vanuatu Pac Health Dialog 8 1 2001 29 37
25. K. Kazama Rapid prevalence of kava drinking in Kiribati, Central Pacific People Cult Oceana 22 2006 85 106
26. M. Merlin, and W. Raynor Kava cultivation, native species conservation, and integrated watershed resource management on Pohnpei Island Pac Sci 59 2 2005 241 260
27. C.S. Côté, C. Kor, J. Cohen, and K. Auclair Composition and biological activity of traditional and commercial kava extracts Biochem Biophys Res Commun 322 1 2004 147 152
28. T.D. Xuan, M. Fukuta, A.C. Wei, A.A. Elzaawely, T.D. Khanh, and S. Tawata Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots J Nat Med 62 2 2008 188 194
29. L.M. Shimoda, C. Park, A.J. Stokes, H.H. Gomes, and H. Turner Pacific island 'awa (kava) extracts, but not isolated kavalactones, promote proinflammatory responses in model mast cells Phytother Res 26 12 2012 1934 1941
30. C.K. Smith, C.A. Moore, E.N. Elahi, A.T. Smart, and S.A. Hotchkiss Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol Toxicol Appl Pharmacol 168 3 2000 189 199
31. A. Stokes, C. Wakano, M. Koblan-Huberson, C.N. Adra, A. Fleig, and H. Turner TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD Cell Signal 18 10 2006 1584 1594
32. L.R. Sadofsky, A.N. Boa, S.A. Maher, M.A. Birrell, M.G. Belvisi, and A.H. Morice TRPA1 is activated by direct addition of cysteine residues to the N-hydroxysuccinyl esters of acrylic and cinnamic acids Pharmacol Res 63 1 2011 30 36
33. E. Middleton, C. Kandaswami, and T.C. Theoharides The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacol Rev 52 4 2000 673
34. K.M. Connor, J.R. Davidson, and L.E. Churchill Adverse-effect profile of kava CNS Spectr 6 10 2001 848 [850-3]
35. L. Rychetnik, and C.M. Madronio The health and social effects of drinking water-based infusions of kava: a review of the evidence Drug Alcohol Rev 30 1 2011 74 83
36. R. Grace Kava-induced urticaria J Am Acad Dermatol 53 5 2005 906
37. S. Hannam, M. Murray, L. Romani, M. Tuicakau, and M. J Whitfeld Dermatomyositis-like illness following kava-kava ingestion JCR J Clin Rheumatol 5 6 1999 342 345
38. S. Hannam, M. Murray, L. Romani, M. Tuicakau, and M. J Whitfeld Kava dermopathy in Fiji: an acquired ichthyosis? Int J Dermatol 53 12 2014 1490 1494
39. J.C. Huynh, M.M. Asgari, and M.M. Moore Sebotropic eruption associated with use of oral kava kava supplement Clin Exp Dermatol 39 7 2014 816 818
40. S.A. Norton, and P. Ruze Kava dermopathy J Am Acad Dermatol 31 1 1994 89 97
41. CDC Hepatic toxicity possibly associated with kava-containing products - United States, Germany, and Switzerland, 1999-2002 Morb Mortal Wkly Rep 51 47 2002 1065 1067
42. R. Bodkin, S. Schneider, D. Rekkerth, L. Spillane, and M. Kamali Rhabdomyolysis associated with kava ingestion Am J Emerg Med 30 4 2012 635 [e1-3]
43. I. Sibon, E. Rosier, and J.M. Orgogozo Meningismus after taking kava-kava Rev Neurol (Paris) 158 12 Pt 1 2002 1205 1206
44. N. Vignier, F. Lert, C. Salomon, and C. Hamelin Kava drinking associated with suicidal behaviour among young Kanaks using kava in New Caledonia Aust N Z J Public Health 35 5 2011 427 433
45. L.R. Olsen, M.P. Grillo, and C. Skonberg Constituents in kava extracts potentially involved in hepatotoxicity: a review Chem Res Toxicol 24 7 2011 992 1002
46. R. Teschke Kava hepatotoxicity - a clinical review Ann Hepatol 9 3 2010 251 265
47. R. Teschke, J. Sarris, and V. Lebot Kava hepatotoxicity solution: a six-point plan for new kava standardization Phytomedicine 18 2-3 2011 96 103
48. R.F. Moulds, and J. Malani Kava: herbal panacea or liver poison? Med J Aust 178 9 2003 451 453
49. J. Sarris, R. Teschke, C. Stough, A. Scholey, and I. Schweitzer Re-introduction of kava (Piper methysticum) to the EU: is there a way forward? Planta Med 77 2 2011 107 110
50. R.A. DiSilvestro, W. Zhang, and D.J. DiSilvestro Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis Food Chem Toxicol 45 7 2007 1293 1300
51. P. Zhou, S. Gross, J.H. Liu, B.Y. Yu, L.L. Feng, and J. Nolta Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways FASEB J 24 12 2010 4722 4732
52. X.L. Zi, and A.R. Simoneau Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice Cancer Res 65 8 2005 3479 3486
53. G.G. Steiner The correlation between cancer incidence and kava consumption Hawaii Med J 59 11 2000 420 422
54. NTP Toxicology and carcinogenesis studies of kava kava extract (CAS NO. 9000-38-8) in F344/N rats and B6C3F1 mice Natl Toxicol Program Tech Rep Ser 571 2012 1 186
55. WHO N-Nitrosodimethylamine in drinking-water; background document for development of WHO Guidelines for Drinking-water Quality Concise International Chemical Assessment Document 2006 38
56. R.G. Lee Chapter 7: fatty change and steatohepatitis Diagnostic liver pathology 1994 Mosby St. Louis
57. J. Anke, and I. Ramzan Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.) J Ethnopharmacol 93 2-3 2004 153 160
58. J.M. Mathews, A.S. Etheridge, and S.R. Black Inhibition of human cytochrome P450 activities by kava extract and kavalactones Drug Metab Dispos 30 11 2002 1153 1157
59. J.M. Mathews, A.S. Etheridge, J.L. Valentine, S.R. Black, D.P. Coleman, and P. Patel Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro Drug Metab Dispos 33 10 2005 1555 1563
60. L. Zou, G.L. Henderson, M.R. Harkey, Y. Sakai, and A. Li Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes Phytomedicine 11 4 2004 285 294
61. M. Ingelman-Sundberg Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 1 2005 6 13
62. N. Poolsup, P. Li Wan, and T. Knight Pharmacogenetics and psychopharmacotherapy J Clin Pharm Ther 25 3 2000 197 220
63. T.P. Toohey, B.Y. Lu, and C. Wada Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava: report of 2 cases Prim Care Companion CNS Disord 15 5 2013
64. S. Wanwimolruk, S. Bhawan, P.F. Coville, and S.C. Chalcroft Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations Eur J Clin Pharmacol 54 5 1998 431 435
65. H.R. Luo, A. Gaedigk, V. Aloumanis, and Y.J. Wan Identification of CYP2D6 impaired functional alleles in Mexican Americans Eur J Clin Pharmacol 61 11 2005 797 802
66. Y.N. Singh Potential for interaction of kava and St. John's wort with drugs J Ethnopharmacol 100 1-2 2005 108 113
67. X. Wang, and S. Zeng Stereoselective metabolic and pharmacokinetic analysis of the chiral active components from herbal medicines Curr Pharm Anal 6 1 2010 39 52
68. J.A. Yáñez, C.M. Remsberg, N.D. Miranda, K.R. Vega-Villa, P.K. Andrews, and N.M. Davies Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices Biopharm Drug Dispos 29 2 2008 63 82
69. Z. Hong, J. Le, M. Lin, G. Fan, Y. Chai, and X. Yin Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats Chirality 20 2 2008 119 124
70. R. Teschke, and V. Lebot Proposal for a kava quality standardization code Food Chem Toxicol 49 10 2011 2503 2516
71. M.J. Balick, and R. Lee Traditional use of sakau (kava) in Pohnpei: lessons for integrative medicine Altern Ther Health Med 8 4 2002 96 98
72. V. Lebot, and P. Simeoni Is the quality of kava (Piper methysticum Forst. f.) responsible for different geographical patternS? Ethnobot Res Appl 2 2004 19 28
73. F. Ellingwood American Materia Medica, theraputics and pharmacognosy [reprint] 1919 Eclectic Medical Publications Portland, OR
74. J. King, H. Wickes Fellwer, and J.U. Lloyd King's American Dispensatory [reprinted 1983] 1905 Eclectic Medical Publications Portland, OR
75. V. Lebot Kava - the Pacific elixir: the definitive guide to its ethnobotany, history, and chemistry M. Merlin, L. Lindstrom, 1997 Healing Arts Press Rochester, VT
76. S. Abadi, C. Papoushek, and M.F. Evans Is kava extract effective for treating anxiety? Can Fam Physician 47 2001 1745 1747
77. K.C. Abraham, K.M. Connor, and J.R. Davidson Explanatory attributions of anxiety and recovery in a study of kava J Altern Complement Med 10 3 2004 556 559
78. R.J. Boerner Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia Phytother Res 15 7 2001 646 647
79. R.J. Boerner, and S. Klement Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490 Wien Med Wochenschr 154 21-22 2004 508 510
80. R.J. Boerner, H. Sommer, W. Berger, U. Kuhn, U. Schmidt, and M. Mannel Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients Phytomedicine 10 Suppl. 4 2003 38 49
81. A. Cagnacci, S. Arangino, A. Renzi, A.L. Zanni, S. Malmusi, and A. Volpe Kava-Kava administration reduces anxiety in perimenopausal women Maturitas 44 2 2003 103 109
82. S. Cairney, P. Maruff, and A.R. Clough The neurobehavioural effects of kava Aust N Z J Psychiatry 36 5 2002 657 662
83. A. Capasso, and L. Sorrentino Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination Phytomedicine 12 1-2 2005 39 45
84. K.M. Connor, and J.R. Davidson A placebo-controlled study of Kava kava in generalized anxiety disorder Int Clin Psychopharmacol 17 4 2002 185 188
85. M. Gastpar, and H.D. Klimm Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial Phytomedicine 10 8 2003 631 639
86. F.P. Geier, and T. Konstantinowicz Kava treatment in patients with anxiety Phytother Res 18 4 2004 297 300
87. D.D. Jamieson, and P.H. Duffield The antinociceptive actions of kava components in mice Clin Exp Pharmacol Physiol 17 7 1990 495 507
88. E. LaPorte, J. Sarris, C. Stough, and A. Scholey Neurocognitive effects of kava (Piper methysticum): a systematic review Hum Psychopharmacol 26 2 2011 102 111
89. J. Sarris, J. Adams, and J.L. Wardle Time for a reassessment of the use of Kava in anxiety? Complement Ther Med 17 3 2009 121 122
90. J. Sarris, D.J. Kavanagh, G. Byrne, K.M. Bone, J. Adams, and G. Deed Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum Complement Ther Med 17 3 2009 176 178
91. J. Sarris, C. Stough, C.A. Bousman, Z.T. Wahid, G. Murray, and R. Teschke Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study J Clin Psychopharmacol 33 5 2013 643 648
92. J. Sarris, C. Stough, R. Teschke, Z.T. Wahid, C.A. Bousman, and G. Murray Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects Phytother Res 27 11 2013 1723 1728
93. D. Loew Kava-kava-extrakt Dtsch Apoth Ztg 142 9 2002 1012 1020
94. C. Cantor Kava and alcohol Med J Aust 167 10 1997 560
95. T.E. Johnson, F. Kassie, M.G. O'Sullivan, M. Negia, T.E. Hanson, and P. Upadhyaya Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice Cancer Prev Res (Phila) 1 6 2008 430 438
96. T.E. Johnson, D. Hermanson, L. Wang, F. Kassie, P. Upadhyaya, and M.G. O'Sullivan Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice Am J Chin Med 39 4 2011 727 742
97. P. Leitzman, S.C. Narayanapillai, S. Balbo, B. Zhou, P. Upadhyaya, and A.A. Shaik Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J mice Cancer Prev Res (Phila) 7 1 2014 86 96
98. J.P. Buckley, A.R. Furgiuele, and M.J. O'Hara The pharmacology of Kava J Polynesian Soc 76 1 1967 101 102
99. H.J. Meyer Pharmacology of Kava Psychopharmacol Bull 4 3 1967 10
100. N. Abu, W.Y. Ho, S.K. Yeap, M.N. Akhtar, M.P. Abdullah, and A.R. Omar The flavokawains: uprising medicinal chalcones Cancer Cell Int 13 1 2013 102
101. L.P. Davies, C.A. Drew, P. Duffield, G.A. Johnston, and D.D. Jamieson Kava pyrones and resin: studies on GABA A, GABA B and benzodiazepine binding sites in rodent brain Pharmacol Toxicol 71 2 1992 120 126
102. C.S. Yuan, L. Dey, A. Wang, S. Mehendale, J.T. Xie, and H.H. Aung Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation Planta Med 68 12 2002 1092 1096
103. S. Ben-Shabat, E. Fride, T. Sheskin, T. Tamiri, M.H. Rhee, and Z. Vogel An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity Eur J Pharmacol 353 1 1998 23 31
104. E.B. Russo Taming THC: potential cannabis synergy and phytocannabinoidâ€FOR VERIFICATION>terpenoid entourage effects Br. J. Pharmacol. 163 7 2011 1344 1364